|
|
|
| Influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high-frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer |
| LIU Lihua1 CAI Jundong1 LIU Yanqin2 ZHENG Yumei1 WANG Haisheng3 DING Baiying1 LI Xiaodong1 LIU Jing4 QIAO Weichao1 DONG Xinhong1 |
1.Chengde Tumour Hospital, Hebei Province, Chengde 067000, China;
2.Longhua County Hospital of Traditional Chinese Medicine, Hebei Province, Chengde 067000, China;
3.Chengde County East White Flag Township Health Center, Hebei Province, Chengde 067000, China;
4.Chengde Maternal and Child Health-Care Hospital, Hebei Province, Chengde 067000, China |
|
|
|
Abstract Objective To explore the influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer. Methods From August 2011 to July 2012, in Chengde Tumour Hospital, 144 patients with locally advanced esophageal cancer were selected, and they were divided into control group (72 cases) and observation group (72 cases) according to the random number table method. The control group was treated with Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy, and the observation group was given ombined with hyperthermia in vitro on the basis of the control group. The rapeutic effect and survival rate in the two groups were contrasted, and toxic and side effects in the two groups were observed. Results The total effective rate of the combination group (86.11%) was significantly higher than that of the control group (62.50%), the difference was statistically significant (P < 0.05). The side effects during the treatment occured in two groups, two groups were compared, the difference was not statistically significant (P > 0.05). Survival rates of 1, 2, 3, 4 years in the observation group (70.83%, 55.56%, 45.83%, 38.89%) were significantly higher than those in the control group (55.56%, 40.27%, 29.17%, 22.22%), the differences were statistically significant (P < 0.05). Conclusion The effect is better of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with hyperthermia in vitro on patients with locally advanced esophageal cancer, with high survival rate. It has a certain promotion value.
|
|
|
|
|
|
| Cite this article: |
|
LIU Lihua1 CAI Jundong1 LIU Yanqin2 ZHENG Yumei1 WANG Haisheng3 DING Baiying1 LI Xiaodong1 LIU Jing4 QIAO Weichao1 DONG Xinhong1. Influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high-frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer[J]. 中国医药导报, 2017, 14(23): 80-83.
|
|
|
|
| URL: |
| http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I23/80 |
[1] 蔡君东，刘晶，曾淑超，等.三维适形放疗不同联合方式治疗中晚期食管癌的对比研究[J].东南大学学报：医学版，2014，33（1）：40-44.
[2] 刘小平，刘锐，施璠，等.食管癌三维适形放疗协同化疗后程加速超分割的临床研究[J].陕西医学杂志，2014，43（10）：1298-1299.
[3] P?觟ttgen C，Eberhardt W，Graupner B，et al. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage ⅢA/B non-small cell lung cancer： Markedly higher rate of pathologic complete remissions than with conventional fractionation [J]. Eur J Cancer，2013，49（9）：2107-2115.
[4] 邵海君，洪伟丰，应军盛，等.后程加速超分割三维适形放疗同步化疗治疗食管癌的疗效分析[J].中国中西医结合消化杂志，2016，24（2）：104-107.
[5] 崔念基，卢泰祥，邓小武.实用临床放射肿瘤学[M].广州：中山大学出版社，2005：471.
[6] 王敏，李基胜，张汉雄，等.后程加速超分割三维适形放疗同步化疗治疗中晚期食管癌的临床研究[J].中国癌症防治杂志，2016，8（3）：150-153.
[7] Taylor RE，Howman AJ，Wheatley K，et al. Hyperfractionated Accelerated Radiotherapy （HART） with maintenance chemotherapy for metastatic （M1-3） Medulloblastoma-a safety/feasibility study [J]. Radiother Oncol，2014，111（1）：41-46.
[8] Gupta T，Kannan S，Ghosh-Laskar S，et al. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma： An adjusted indirect comparison meta-analysis [J]. Head Neck，2015，37（5）：670-676.
[9] 许明君，王钇力，郭海亮，等.食管癌后程加速超分割放疗联合同期化疗的临床研究[J].实用肿瘤杂志，2013，28（4）：405-407.
[10] 王海峰.热放疗、放化疗和单纯放疗治疗食管癌临床比较分析[J].亚太传统医药，2013，9（8）：140-141.
[11] 蔡君东，刘晶，曾淑超，等.三维适形放疗联合周剂量奈达铂及体外高频热疗治疗中晚期食管癌的临床研究[J].现代肿瘤医学，2013，21（12）：2715-2718.
[12] Takeda Y，Nakamori S，Eguchi H，et al. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma [J]. Jpn J Clin Oncol，2014，44（12）：1172-1180.
[13] 张远净，吴双，岳国军，等.中晚期可切除食管癌术后放化疗与单纯手术对比的Meta分析[J].中国医药导报，2017，14（5）：94-98.
[14] 李有强，王武峰，彭少华.后程加速超分割放疗联合同步化疗治疗晚期下咽低分化癌疗效观察[J].现代中西医结合杂志，2016，25（30）：3367-3369.
[15] 李基胜.后程加速超分割放疗联合化疗治疗中晚期食管癌的近期疗效观察[J].中国现代药物应用，2013，7（7）：23-24.
[16] 刘丽华，蔡君东，刘艳琴，等.周剂量奈达铂同步后程加速超分割放疗联合体外高频热疗对局部晚期食管癌患者疗效及生存率的影响[J].中国医药导报，2017，14（11）：87-90.
[17] 蔡凯，苏齐鉴，胡联民，等.中晚期食管癌后程加速超分割适形放疗同期化疗的临床观察[J].现代肿瘤医学，2012， 20（3）：523-526.
[18] 康振朝，朱晓梅，赵文永，等.再程超分割放疗联合高频热疗及毫米波治疗局部复发食管癌近期疗效观察[J].甘肃医药，2016，35（4）：301-303.
[19] 侯盘长，许妍，雒建超，等.三维适形放疗同步替吉奥治疗老年术后复发食管癌的效果观察[J].中国医药导报，2014，11（8）：41-43，47.
[20] 纪媛媛，洪永贵，李军扩.紫杉醇脂质体与传统紫杉醇联合顺铂治疗晚期食管癌的疗效对比研究[J].肿瘤基础与临床，2013，26（4）：301-303.
[21] 陈丽，汪步海，袁一枫，等.调强放疗联合紫杉醇加奈达铂及重组改构人肿瘤坏死因子α治疗局部进展期食管癌的近期疗效临床观察[J].癌症进展，2016，14（11）：1121-1123，1127.
[22] 赵一虹，许卫东，张富利，等.TOMOX方案联合三维适形放射治疗中晚期食管癌的近期疗效及不良反应观察[J].中国医学装备，2016，13（10）：61-64. |
|
|
|
